Policy and Legislation
HRSA is scheduled to issue approvals to drugmakers by Oct. 15 for implementation of the pilot on Jan. 1, 2026.
The main reason for the increase is the expected end of the premium tax credits.
The deal with Pfizer will reduce the price of the company’s prescription drugs for Medicaid to Most Favored Nation pricing.
Medicare and Medicaid reimbursement will continue, but Medicaid payments are dependent on federal appropriation.
Growth in SNPs comprises nearly half of the total increase in MA enrollment since 2018.
That includes a $7.7 billion increase in demand for uncompensated care, numbers showed.
The president says he will impose the tariffs on non-generic drugs unless manufacturers build plants in America.
The monthly premium will fall to $14, and benefit options will remain stable, CMS says.
The legislation is endorsed by numerous healthcare groups, including the American Hospital Association.
FDA will begin notifying physicians that pregnant women should avoid taking Tylenol during pregnancy unless absolutely necessary.